Article
High-dose IV ascorbic acid therapy for patients with CCUS with TET2 mutations.
Blood - 5 Dec 2024
Xie Zhuoer, Fernandez Jenna, Lasho Terra, Finke Christy, Amundson Michelle, McCullough Kristen B, LaPlant Betsy R, Mangaonkar Abhishek A, Gangat Naseema, Reichard Kaaren K, Elliott Michelle, Witzig Thomas E, Patnaik Mrinal M
Abstract excerpt
ABSTRACT: This phase 2 trial assessed high-dose IV ascorbic acid in TET2 mutant clonal cytopenia. Eight of 10 patients were eligible for response assessment, with no responses at week 20 by International Working Group Myelodysplasia Syndromes/Neoplasms criteria. This trial was registered at www.clinicaltrials.gov as #NCT03418038.
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.